首页> 美国卫生研究院文献>ISRN AIDS >Emergence of Drug Resistance in Human Immunodeficiency Virus Type 1 Infected Patients from Pune India at the End of 12 Months of First Line Antiretroviral Therapy Initiation
【2h】

Emergence of Drug Resistance in Human Immunodeficiency Virus Type 1 Infected Patients from Pune India at the End of 12 Months of First Line Antiretroviral Therapy Initiation

机译:一线抗逆转录病毒疗法启动后12个月末来自印度普纳的人类免疫缺陷病毒1型感染患者的耐药性出现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction. In India, 4,86,173 HIV infected patients are on first line antiretroviral therapy (ART) as of January 2012. HIV drug resistance (HIVDR) is drug and regimen-specific and should be balanced against the benefits of providing a given ART regimen. Material & Methods. The emergence of HIVDR mutations in a cohort of 100 consecutive HIV-1 infected individuals attending ART centre, on first line ART for 12 months, was studied. CD4+ T-cell counts and plasma HIV-1 RNA level were determined. Result. Out of the 100 HIV-1 infected individuals, 81 showed HIVDR prevention (HIV-1 RNA level < 1000/mL), while the remaining 19 had HIV-1 viral RNA level > 1000/mL. HIVDR genotyping was carried out for individuals with evidence of virologic failure (HIV-1 RNA level > 1000/mL). The most frequent NRTI-associated mutation observed was M184V, while K103N/S was the commonest mutation at NNRTI resistance position. Conclusion. Our study has revealed the emergence of HIVDR in HIV-1 infected patients at the end of 12 months of first line ART initiation. For NRTIs, the prevalence of HIVDR mutations was 9% and 10% for NNRTIs. Our findings will contribute information in evidence-based decision making with reference to first and second line ART delivery and prevention of HIVDR emergence.
机译:介绍。截至2012年1月,印度有4,86,173名HIV感染患者正在接受一线抗逆转录病毒治疗(ART)。HIV耐药性(HIVDR)是针对药物和治疗方案的,应在提供给定抗病毒治疗方案的益处之间取得平衡。材料与方法。研究了在第一线抗病毒治疗12个月内进入ART中心的100名连续HIV-1感染者队列中HIVDR突变的出现。测定CD4 + T细胞计数和血浆HIV-1 RNA水平。结果。在100例受HIV-1感染的个体中,有81例表现出HIVDR预防作用(HIV-1 RNA水平<1000 / mL),其余19例具有HIV-1病毒RNA水平> 1000 / mL。对有病毒学失败证据的个体(HIV-1 RNA水平> 1000 / mL)进行HIVDR基因分型。观察到的最常见的与NRTI相关的突变是M184V,而K103N / S是在NNRTI抗性位置最常见的突变。结论。我们的研究表明,在一线抗病毒治疗开始12个月后,HIV-1感染患者中出现了HIVDR。对于NRTI,HIVDR突变的发生率分别为9%和10%。我们的发现将为基于证据的决策提供信息,涉及一线和二线抗病毒治疗以及预防HIVDR的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号